Pharma Giants Unite for mRNA Therapy
Arcturus Therapeutics Collaborates With Thermo Fisher to Accelerate ARCT-032's Phase 3 Development
Anonymous
Key Points
1
Arcturus shares rose 5.8% to $7.29 in premarket trading following the Thermo Fisher collaboration announcement, with the stock up about 12% year-to-date.
2
Thermo Fisher will provide up to $40 million in clinical manufacturing for ARCT-032, while Arcturus will engage Thermo Fisher’s PPD unit for up to $40 million in clinical research services; the arrangement covers Phase 3 manufacturing, clinical trial supply, and related technical services (including technical transfer, engineering batches, fill-finish, release and stability studies).
3
The collaboration is frameworked through a Master Services Agreement (MSA) between Thermo Fisher and Arcturus, with a Project Agreement via Patheon UK Limited; CRO services will be provided through PPD, Thermo Fisher’s affiliate, establishing an integrated CDMO/CRO framework for ARCT-032.
4
Thermo Fisher’s Accelerator Drug Development model—combining manufacturing, clinical research, and commercialization—was highlighted as a key driver; Arcturus’ CEO Joseph Payne and Thermo Fisher executive Mike Shafer described the integrated approach as vital to efficiently advancing ARCT-032 toward Phase 3 and potential commercialization.
5
The public disclosure on July 2, 2026 underscored a broader industry shift toward integrated outsourcing for complex mRNA programs and noted Accelerator Drug Development as a core enabler for advancing ARCT-032 from later-stage development toward potential market entry.
Arcturus Therapeutics and Thermo Fisher Scientific announced a major partnership on July 2, 2026, to push the cystic fibrosis drug ARCT-032 into Phase 3 trials. Arcturus shares jumped 5.8% to $7.29 in premarket trading on the news, putting the stock up roughly 12% for the year, according to MarketScreener.
The deal is worth up to $80 million in total. Thermo Fisher will provide up to $40 million in manufacturing support and up to $40 million in clinical research services through its PPD unit, Morningstar reported. Thermo Fisher also secured exclusive commercial manufacturing rights for a set period if the drug wins approval.
What the $80 Million Deal Actually Covers
The partnership runs through a Master Services Agreement signed on June 26, 2026. Patheon UK Limited, a Thermo Fisher unit, will handle the manufacturing side — things like technical transfer, engineering batches, fill-finish, and stability testing. PPD, Thermo Fisher's clinical research arm, will manage the Phase 3 trial itself, according to Morningstar.
Thermo Fisher calls this model "Accelerator Drug Development." It combines manufacturing and clinical research under one roof. The idea is to cut the friction that comes from running those two operations separately. Arcturus CEO Joseph Payne said Thermo Fisher is "aligned with Arcturus' goal of efficiently advancing our cystic fibrosis program into Phase 3."
A Drug Aimed at CF Patients Left Behind by Trikafta
ARCT-032 is an inhaled mRNA therapy. It works by delivering a working copy of the CFTR gene directly into the lungs. Current CF drugs like Vertex's Trikafta only help patients with certain mutations. About 10% of CF patients have so-called Class I mutations and do not respond to those drugs. ARCT-032 targets that group.
Phase 2 data from October 2025 was mixed. Shares crashed 55% in a single day when the drug failed to hit a key lung function target — a 3% improvement in FEV1. But imaging data did show a reduction in mucus plugs, which analysts at William Blair called a signal of "potential for clinical benefit at a high dose," according to Investing.com.
Arcturus Is Betting Big Despite a Shaky Financial Picture
Arcturus reported Q1 2026 earnings on May 8. The company beat EPS estimates, posting a loss of $0.95 per share versus an expected loss of $1.12. But revenue is declining. The stock sits far below its 52-week high of $24.17, and its market cap is roughly $196 million, Investing.com noted.
The company does hold more cash than debt, which gives it runway for the $80 million commitment. Final 12-week Phase 2 data is expected later in 2026. That data will decide whether a pivotal Phase 3 trial moves forward. If it does, this deal puts the pieces in place to move fast.
Why the Industry Is Watching This Model Closely
Thermo Fisher's Mike Shafer, EVP of Biopharma Services, said biotech companies "increasingly seek strategic collaborators that can support complex development programs across clinical and commercial stages." The ARCT-032 deal is a test case for that idea. mRNA drugs require specialized delivery technology and cold-chain logistics, making the integrated approach especially valuable, Morningstar reported.
If ARCT-032 eventually wins approval, Thermo Fisher locks in exclusive commercial manufacturing rights for a defined period. That gives Thermo Fisher a long-term revenue stream and gives Arcturus a stable supply chain from day one. For both companies, the stakes go well beyond this single drug.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
13
Articles
23
Reach
36
A
AnonymousAuthor
